ARAY Accuray Inc Final Profit

Corporate emblem and logo of Accuray (ARAY)

This daily price chart for Accuray Incorporated (ARAY) reflects profit dynamics, which currently stand at -0.05. Accuray Incorporated develops high-precision tumor treatment systems, advancing CyberKnife and penetrating the Chinese market through AI solutions. The business relies on the implementation of real-time adaptive radiation, enabling the company to attract new medical centers amidst fierce competition.

ARAY (Accuray Incorporated) Net Profit history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Accuray (ARAY)

- stock value and consensus price forecast:
Market Price Accuray, Inc.|ARAY - Price Target Chart
- market capitalization data:
Market Value Accuray, Inc.|ARAY - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Accuray Incorporated|ARAY - Book Capitalization|Market Cap to Net Assets Ratio accuray.com|ARAY - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Accuray Incorporated|ARAY - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Accuray Inc|ARAY - Company Aggregate Debts|Debts to Book Value Accuray, Inc.|ARAY - Company Long-Term Debts|Company Short-Term Debts Accuray Incorporated|Quick Liquidity Indicator accuray.com
- net income and valuation multiples indicators:
ARAY - Net Profit
Fundamental valuation:ARAY Accuray, Inc.
Manufactured product of Accuray Inc

Analyzing Accuray Incorporated through the company's earnings allows for an objective assessment of the issuer's financial stability. This indicator captures net income per share, filtering out market noise and emotional price fluctuations. The metric is calculated as the remaining funds after deducting all operating expenses and taxes. For Accuray Incorporated (ARAY), this figure is sensitive to the costs associated with the complex transportation of radiation therapy systems. Stable earnings growth confirms the efficiency of managing high-cost equipment logistics.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Profit SLS|Net Profit actuatetherapeutics.com (ACTU)|Net Profit CTOR (Citius Oncology)|HURA - Net Income|Protara - Net Profit|Fate Pharma (FATE) - Net Income|WHWK (aadibio.com) - Net Income|TScan Therapeutics, Inc. (TCRX) - Net Profit|Company Net Income Champions Oncology Inc|XBIT: Final Profit|Net Profit CVM|Net Profit OS Therapies, Inc. (OSTX)|Radiopharm Theranostics Limited - Net Income|Artiva Biotherapeutics Inc. (ARTV) - Company Net Income|ANL: Net Income|Final Profit VERU (Veru Inc)|TPST: Net Profit|XLO - Net Financial Result|Company Net Income Renovaro Biosciences|Company Profit MURA (Mural Bio)|Net Profit KAPA|Net Income onkuretherapeutics.com OKUR|Company Net Income CytoMed Therapeutics Limited GDTC|Curis Inc. (CRIS) - Company Net Income|APLM - Company Net Income|Final Profit THAR (tharimmune.com)|advanbiomed.com (ADVB) - Company Net Income|Profit After Tax GNPX (Genprex Inc.)|Company Net Income Calidi Biotherapeutics Inc.|Company Net Income Sunshine Biopharma Inc. SBFM|Company Net Income Xenetic Biosciences (XBIO)|SLRX (salariuspharma.com) - Final Profit|Net Profit PPBT (Purple Biotech Ltd.)|Net Profit American Oncology Network Inc AONC|BGNE: Net Income|Checkpoint Therapeutics Inc - Profit After Payment of Taxes|ELEV: Net Profit|Company Net Income iCAD (ICAD)|IKNA (Ikena Oncology Inc.) - Net Profit|Company Profit NTBL (Notable Labs Ltd)|Net Profit VIRX|Net Profit MorphoSys Corporation (MOR)|Company Net Income NAYA Biosciences NAYA|Final Profit AAPGV